Both the size of the pain drug pipeline and venture capital investment in this space over the past decade pale in comparison with the oncology space, according to a new report, which may be explained by the relatively low rate of success for pain therapeutics.
BIO Report: Attrition Higher For Novel Pain Candidates Than In Other Diseases, Funding Lacking
A new report released during the BIO CEO conference shows novel pain therapy candidates face a high failure rate, which may help explain why smaller, privately held biotechs aren't very active in the space.
More from R&D
More from Scrip
• By
Paul Stoffels, the J&J research veteran who helmed Galapagos during a crucial period, will retire upon the appointment of a new CEO as the company continues its latest transformation.
• By
The biotech reported Phase I multiple-ascending dose data for its obesity drug for the second time in a week, but its safety and tolerability do not offset concerns about relatively unimpressive weight reduction.
• By
The company said the main reason for expanding its manufacturing capacity was its growing US commercial portfolio and clinical pipeline.